Oculis Holding AG(OCS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:00 PM ET (Korea 10/29 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.76 | Insider Own | 23.77% | Shs Outstand | 61.7M | Perf Week | 1.4% |
| Market Cap | 0.49B | Forward P/E | - | EPS next Y | -11.63% | Insider Trans | - | Shs Float | 47.1M | Perf Month | -12.6% |
| Enterprise Value | 0.21B | PEG | - | EPS next Q | -0.49 | Inst Own | 27.04% | Short Float | 3.8% | Perf Quarter | -28.81% |
| Income | -0.10B | P/S | - | EPS this Y | 18.21% | Inst Trans | 8.92% | Short Ratio | 6.79 | Perf Half Y | -69.83% |
| Sales | 0.00B | P/B | 1.81 | EPS next 5Y | 5.05% | ROA | -37.11% | Short Interest | 1.79M | Perf YTD | -60.04% |
| Book/sh | 4.4 | P/C | 1.74 | EPS past 3/5Y | -26.82% - | ROE | -44.24% | 52W High | -76.85% ($34.47) | Perf Year | -62% |
| Cash/sh | 4.59 | P/FCF | - | Sales past 3/5Y | - | ROIC | -36.45% | 52W Low | 12.24% ($7.11) | Perf 3Y | -16.35% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 34.21% | Gross Margin | - | Volatility(W/M) | 6.02% 5.69% | Perf 5Y | -17.82% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.47 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.35 | EPS Q/Q | 64.92% | Profit Margin | - | RSI (14) | 40.23 | Recom | 1.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.35 | Sales Q/Q | - | SMA20 | -0.29% ($8) | Beta | 0.27 | Target Price | $36.81 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/6 | SMA50 | -19.82% ($9.95) | Rel Volume | 0.84 | Prev Close | $7.83 |
| Employees | 60 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 58.87% 71.46% | SMA200 | -57.94% ($18.97) | Avg Volume(3M) | 0.26M | Price | $7.98 |
| IPO | 2021/5/18 | Option/Short | Yes/Yes | Trades | 2505 | Volume | 219,980 | Change | 1.92% |
👁️ Oculis Holding (ticker OCS) is a global clinical-stage biopharmaceutical company targeting unmet medical needs in ophthalmology and neuro-ophthalmology. Leveraging proprietary eye-drop-based delivery technology, the company is developing a pipeline of novel drug candidates across multiple indications, including diabetic macular edema, dry eye disease, and optic nerve disorders. Oculis operates with a dual-listing structure, traded on both Nasdaq and the Icelandic stock exchange.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded about as much as usual. That is 84% of its average volume.
OCS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +18.2% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -17.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 27.0%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #223 of 594 in the industry
Based on market cap of $493M.
FAQ
What kind of company is OCS?
OCS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OCS?
The market cap of OCS is approximately $493M, ranking 3,173 within its sector.
What is the 52-week high and low for OCS?
OCS has recorded a 52-week high of $34.47 and a low of $7.11.
